Glucagon-like peptide 1 receptor agonists (GLP1RAs) have been recommended for preventing cardiorenal events in patients with type 2 diabetes (T2D) [1], and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been recommended for doing this in patients with T2D, heart failure (HF), or chronic kidney disease [1–3]. Although these two classes of novel antidiabetics can exert the cardiovascular benefits [4,5], up to now they have not been recommended to be used in individual cardiovascular diseases, such as coronary heart disease (CHD) and essential hypertension.
